Passage Bio Inc Ordinary Shares PASG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote — UTZ, SAFT, PASG and FNWD
EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD - IS IT A FAIR DEAL FOR YOU?
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
Trading Information
- Previous Close Price
- $3.51
- Day Range
- $3.39–3.56
- 52-Week Range
- $3.29–20.00
- Bid/Ask
- $3.32 / $3.85
- Shares Outstanding
- 3.22M
- Market Cap
- $11.13M
- Volume/Avg
- 28,146 / 19,500
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.passagebio.com
Valuation
Metric | PASG |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PASG |
|---|---|
Quick Ratio | 1.17 |
Current Ratio | 1.22 |
Interest Coverage | — |
Quick Ratio
PASG
Profitability
Metric | PASG |
|---|---|
Return on Assets (Normalized) | −59.29% |
Return on Equity (Normalized) | −157.56% |
Return on Invested Capital (Normalized) | −89.75% |
Return on Assets
PASG
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Fr%@$# | LOCK|@@!& | $138B | |||
| Moderna Inc MRNA | LOCK|kXYQsb | LOCK|nJ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#sQ&#mH | LOCK|wp^?X | $93B | |||
| argenx SE ADR ARGX | LOCK|V>#D#&W | LOCK|>t | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?J#Yw#N | LOCK|FJ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|pkBJQ>P | LOCK|>m%T | $30B | |||
| Incyte Corp INCY | LOCK|Yn<nT! | LOCK|%R | $24B | |||
| BioNTech SE ADR BNTX | LOCK|F!xQb$k | LOCK|lg | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|rPWxDbl | LOCK|jBD#T | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|K#B!myl | LOCK|&pT | $15B |
United States